These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 29924855)

  • 1. Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project.
    Pérez-Rodríguez A; Batlle J; Corrales I; Borràs N; Rodríguez-Trillo Á; Lourés E; Cid AR; Bonanad S; Cabrera N; Moret A; Parra R; Mingot-Castellano ME; Navarro N; Altisent C; Pérez-Montes R; Marcellini S; Moreto A; Herrero S; Soto I; Fernández Mosteirín N; Jiménez-Yuste V; Alonso N; de Andrés Jacob A; Fontanes E; Campos R; Paloma MJ; Bermejo N; Berrueco R; Mateo J; Arribalzaga K; Marco P; Palomo Á; Castro Quismondo N; Iñigo B; Nieto MDM; Vidal R; Martínez MP; Aguinaco R; Tenorio M; Ferreiro M; García-Frade J; Rodríguez-Huerta AM; Cuesta J; Rodríguez-González R; García-Candel F; Dobón M; Aguilar C; Batlle F; Vidal F; López-Fernández MF
    PLoS One; 2018; 13(6):e0197876. PubMed ID: 29924855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm.
    Batlle J; Pérez-Rodríguez A; Corrales I; López-Fernández MF; Rodríguez-Trillo Á; Lourés E; Cid AR; Bonanad S; Cabrera N; Moret A; Parra R; Mingot-Castellano ME; Balda I; Altisent C; Pérez-Montes R; Fisac RM; Iruín G; Herrero S; Soto I; de Rueda B; Jiménez-Yuste V; Alonso N; Vilariño D; Arija O; Campos R; Paloma MJ; Bermejo N; Toll T; Mateo J; Arribalzaga K; Marco P; Palomo Á; Sarmiento L; Iñigo B; Nieto Mdel M; Vidal R; Martínez MP; Aguinaco R; César JM; Ferreiro M; García-Frade J; Rodríguez-Huerta AM; Cuesta J; Rodríguez-González R; García-Candel F; Cornudella R; Aguilar C; Borràs N; Vidal F
    Thromb Haemost; 2016 Jan; 115(1):40-50. PubMed ID: 26245874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. von Willebrand disease R1374C: type 2A or 2M? A challenge to the revised classification. High frequency in the northwest of Spain (Galicia).
    Penas N; Pérez-Rodríguez A; Torea JH; Lourés E; Noya MS; López-Fernández MF; Batlle J
    Am J Hematol; 2005 Nov; 80(3):188-96. PubMed ID: 16247740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort.
    Borràs N; Garcia-Martínez I; Batlle J; Pérez-Rodríguez A; Parra R; Altisent C; López-Fernández MF; Costa Pinto J; Batlle-López F; Cid AR; Bonanad S; Cabrera N; Moret A; Mingot-Castellano ME; Navarro N; Pérez-Montes R; Marcellini S; Moreto A; Herrero S; Soto I; Fernández-Mosteirín N; Jiménez-Yuste V; Alonso N; de Andrés-Jacob A; Fontanes E; Campos R; Paloma MJ; Bermejo N; Berrueco R; Mateo J; Arribalzaga K; Marco P; Palomo Á; Castro Quismondo N; Iñigo B; Del Mar Nieto M; Vidal R; Martínez MP; Aguinaco R; Tenorio M; Ferreiro M; García-Frade J; Rodríguez-Huerta AM; Cuesta J; Rodríguez-González R; García-Candel F; Dobón M; Aguilar C; Corrales I; Vidal F
    Thromb Haemost; 2020 Mar; 120(3):437-448. PubMed ID: 32135566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-phenotype correlation in a cohort of Portuguese patients comprising the entire spectrum of VWD types: impact of NGS.
    Fidalgo T; Salvado R; Corrales I; Pinto SC; Borràs N; Oliveira A; Martinho P; Ferreira G; Almeida H; Oliveira C; Marques D; Gonçalves E; Diniz M; Antunes M; Tavares A; Caetano G; Kjöllerström P; Maia R; Sevivas TS; Vidal F; Ribeiro L
    Thromb Haemost; 2016 Jul; 116(1):17-31. PubMed ID: 26988807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of inherited von Willebrand disease: comparison of two methodologies and analysis of the discrepancies.
    Costa-Pinto J; Pérez-Rodríguez A; del C Goméz-del-Castillo M; Lourés E; Rodríguez-Trillo A; Batlle J; López-Fernández MF
    Haemophilia; 2014 Jul; 20(4):559-67. PubMed ID: 25077350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF.
    Jousselme E; Jourdy Y; Rugeri L; Négrier C; Nougier C
    Int J Lab Hematol; 2018 Feb; 40(1):77-83. PubMed ID: 28980759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD).
    Tosetto A; Rodeghiero F; Castaman G; Bernardi M; Bertoncello K; Goodeve A; Federici AB; Batlle J; Meyer D; Mazurier C; Goudemand J; Eikenboom J; Schneppenheim R; Budde U; Ingerslev J; Vorlova Z; Habart D; Holmberg L; Lethagen S; Pasi J; Hill F; Peake I
    J Thromb Haemost; 2007 Apr; 5(4):715-21. PubMed ID: 17408405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a fully automated von Willebrand factor assay panel for the diagnosis of von Willebrand disease.
    Stufano F; Baronciani L; Bucciarelli P; Boscarino M; Colpani P; Pagliari MT; Peyvandi F
    Haemophilia; 2020 Mar; 26(2):298-305. PubMed ID: 32107842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin.
    Graf L; Moffat KA; Carlino SA; Chan AK; Iorio A; Giulivi A; Hayward CP
    Int J Lab Hematol; 2014 Jun; 36(3):341-51. PubMed ID: 24750681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients.
    Borràs N; Batlle J; Pérez-Rodríguez A; López-Fernández MF; Rodríguez-Trillo Á; Lourés E; Cid AR; Bonanad S; Cabrera N; Moret A; Parra R; Mingot-Castellano ME; Balda I; Altisent C; Pérez-Montes R; Fisac RM; Iruín G; Herrero S; Soto I; de Rueda B; Jiménez-Yuste V; Alonso N; Vilariño D; Arija O; Campos R; Paloma MJ; Bermejo N; Berrueco R; Mateo J; Arribalzaga K; Marco P; Palomo Á; Sarmiento L; Iñigo B; Nieto MDM; Vidal R; Martínez MP; Aguinaco R; César JM; Ferreiro M; García-Frade J; Rodríguez-Huerta AM; Cuesta J; Rodríguez-González R; García-Candel F; Cornudella R; Aguilar C; Vidal F; Corrales I
    Haematologica; 2017 Dec; 102(12):2005-2014. PubMed ID: 28971901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing of von Willebrand factor and coagulation factor VIII genes: a cross-sectional study in Croatian adult patients diagnosed with von Willebrand disease.
    Lapić I; Radić Antolic M; Boban A; Coen Herak D; Rogić D; Zadro R
    Croat Med J; 2022 Apr; 63(2):166-175. PubMed ID: 35505650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.